Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC

Barclays PLC raised its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 276.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 273,085 shares of the biopharmaceutical company’s stock after buying an additional 200,482 shares during the period. Barclays PLC owned approximately 0.13% of Akebia Therapeutics worth $360,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of AKBA. State Street Corp raised its stake in Akebia Therapeutics by 24.9% during the 3rd quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company’s stock valued at $4,528,000 after purchasing an additional 683,287 shares during the period. Bank of New York Mellon Corp raised its stake in Akebia Therapeutics by 3,122.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 604,551 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 585,789 shares during the period. Wellington Management Group LLP acquired a new stake in Akebia Therapeutics during the 3rd quarter valued at $534,000. Renaissance Technologies LLC raised its stake in Akebia Therapeutics by 7.2% during the 2nd quarter. Renaissance Technologies LLC now owns 3,914,800 shares of the biopharmaceutical company’s stock valued at $3,993,000 after purchasing an additional 262,700 shares during the period. Finally, Rhumbline Advisers raised its stake in Akebia Therapeutics by 4,915.4% during the 2nd quarter. Rhumbline Advisers now owns 247,060 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 242,134 shares during the period. Institutional investors own 33.92% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on AKBA shares. StockNews.com downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Wednesday, October 23rd.

Akebia Therapeutics Trading Up 1.1 %

Shares of NASDAQ:AKBA opened at $1.92 on Friday. The stock has a market capitalization of $418.91 million, a PE ratio of -8.35 and a beta of 0.72. Akebia Therapeutics, Inc. has a 1 year low of $0.80 and a 1 year high of $2.48. The firm has a fifty day moving average price of $1.89 and a 200 day moving average price of $1.51.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The company had revenue of $37.43 million for the quarter, compared to analysts’ expectations of $45.66 million. During the same period in the previous year, the company earned ($0.08) EPS. On average, sell-side analysts forecast that Akebia Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.